The InvisiMask nasal spray is an investigational daily human antibody nasal spray designed to neutralize SARS-CoV-2, the virus that causes COVID-19, from airborne droplets and particles in the nasal cavity, the primary entry point of SARS-CoV-2 infection.
At the lowest dose of 25μg, the antibodies provided at least 10 hours of protection against infection in mice exposed to the highest viral load tested (107 virus particles administered intra-nasally).
Potential of the InvisiMask nasal spray
We envision the InvisiMask nasal spray to be used daily to provide an important line of personal protection against SARS-CoV-2 infection.
How does the InvisiMask nasal spray work?
Antibodies administered by InvisiMask nasal spray
Antibodies adhere to the upper respiratory tract
Antibodies neutralize the SARS-CoV-2 virus
The Eureka antibodies function by binding to the S1 spike protein of SARS-CoV-2 and preventing the virus from binding to the ACE2 receptor on cells in the upper respiratory system. This blocks SARS-CoV-2 from entering cells and triggering an infection.
Key attributes and advantages of the InvisiMask nasal spray
Key Attributes | Advantages |
Nasal spray format |
|
Anti-SARS-CoV-2 human IgG antibodies |
|
High Affinity and Specificity Antibodies |
|
Proprietary Adhesion Technology |
|
Paper
Intranasal administration of SARS-CoV-2 neutralizing human antibody prevents infection in mice, see data posted on bioRxiv
FAQ
Frequently Asked Questions about the InvisiMask
Current Status
Eureka is preparing an Investigational New Drug (IND) application with the FDA to conduct a clinical trial of the InvisiMask nasal spray.
Inquiries
For inquiries, e-mail: invisimask@eurekaninc.com